38 results about "Dextran Sulfate Sodium" patented technology

The invention discloses bifidobacterium longum and the application thereof and belongs to the technical field of biologics. The invention provides a bifidobacterium longum YS108R strain which has thecharacteristic of generating viscous exopolysaccharide, and has a remarkable improvement function on DSS (Dextran Sulfate Sodium) induced mouse colitis models. The strain has a relatively good capability of enduring simulated gastrointestinal fluids, is capable of remarkably reducing disease activity indexes of mice in the DSS induction period, and has an effective protection function on colon tissue. In addition, the bifidobacterium longum YS108R disclosed by the invention is separated from intestinal florae of healthy people, is free of toxic and / or side effects on human bodies, and has certain advantages when being compared with conventional medicine treatment. The strain can be used for preparing probiotic powder, fermented milk, and the like, and has wide market prospects.

The invention discloses a BMP-2 (Bone Morphogenetic Protein-2) sustained release microsphere and a preparation method thereof. The preparation method of the BMP-2 sustained release microsphere comprises the following steps of: dissolving chitosan in an aqueous solvent so as to obtain a chitosan solution; dissolving BMP-2 into a dextran sulfate sodium aqueous solution, dropwise adding the chitosan solution into the dextran sulfate sodium aqueous solution under the condition of stirring, then adding a metal salt so as to form the microsphere in a reaction solution, washing and freeze-drying so as to obtain the BMP-2 sustained release microsphere. The matrix component of the microsphere prepared by using the method comprises chitosan and dextran sulfate sodium, the wrapped medicine is BMP-2, the average particle size of the microsphere is 200-900nm, the encapsulation efficiency can be 75-90%, and the BMP-2 is long in protein activity duration and sustained release period. The BMP-2 sustained release microsphere is simple in preparation process, low in production cost, easy to carry out, and mild in reaction condition, and does not need the addition of reagents which can influence the protein activity of BMP-2; and the e microsphere is round and complete in appearance, good in polydispersity, non-sticky after being freeze-dried and soluble in water.

The invention relates to a method for preparing the protamine and dextran sulfate sodium microcapsule, comprising the following steps: reacting calcium chloride, sodium carbonate, sodium polystyrene sulfonate or polyallylamine hydrochloride, cetyl trimethyl ammonium bromide, PEO20-PPO70-PEO20 triblock copolymer, polydiallyldimethylamine chloride solution with stirring at the temperature of 10 to 80 DEG C to obtain the calcium carbonate microsphere; fully mixing the obtained calcium carbonate microsphere with the protamine water solution, adsorbing the protamine, removing the protamine not to be adsorbed, fully mixing the calcium carbonate microsphere with the protamine withdextran sulfate sodium containing inorganic salt to adsorb dextran sulfate sodium, removing the dextran sulfate sodium not to be adsorbed; alternately adsorbing to obtain the microcapsule with the protamine and dextran sulfate sodium multilayer membrane core-shell structure; dissolving calcium carbonate in ethylenediaminetetraacetic acid sodiumsalt to obtain the protamine and dextran sulfate sodium microcapsule.

The invention discloses a new Akkermansia muciniphila 139 strain. The strain is collected in the China General Microbiological Culture Collection Center with a collection number of CGMCC No. 16758, and a collection date is November 21st, 2018. The invention also discloses a purpose of the strain. Through separation and authentication, a new strain, i.e., the Akkermansia muciniphila 139, of Akkermansia muciniphila is obtained, the strain can carry out fermentation in vitro to generate a great quantity of short chain fatty acids, and the intestinal health of a host can be maintained. The fermentation in vitro of supernatant can induce the differentiation of mice lymphocyte regulative T cells, and the immunologic function of the host is enhanced. In addition, the bacteria strain also can alleviate enteritis, especially DSS (dextran sulfate sodium)-induced chronic enteritis, and also has a probiotic function.

The invention discloses test paper for measuring high density lipoprotein cholesterol and a preparation method and application thereof. The test paper comprises a red blood cell separation layer, an auxiliary separation layer and a reaction layer, wherein the red blood cell separation layer, the auxiliary separation layer and the reaction layer are prepared from a separation material, a separationmembrane and a reaction membrane through carrying out steeping by red blood cell separation solution, auxiliary separation solution and reaction solution and then carrying out drying; the red blood cell separation solution comprises the following components: buffer salt, a divalent metal ion, dextran sulfate sodium salt with a molecular weight of 30000-500000, hemagglutinin or an Anti-RBC antibody; the auxiliary separation solution comprises the following components: buffer salt, a surfactant I and polyhydric alcohol; and the reaction solution comprises the following components: buffer salt,a surfactant II, polysaccharide, cholesterol esterase, cholesterol oxidase, peroxidase, ascorbic acid oxidase, an oxidizing substance and a color developing agent. The test paper is capable of simplyand rapidly detecting the contents of high density lipoprotein cholesterol. The invention furthermore provides a preparation method and application of the test paper.

The invention provides a strain of clostridiumbutyricum for preventing ulcerative colitis. The strain is preserved in CGMCC (China General Microbiological Culture Collection Center) on May 27, 2019, and the preservation number is CGMCC NO.17854. A C57BL / 6N mouse is used as an experiment object; DSS (Dextran Sulfate Sodium) is used for inducing the mouse to form an ulcerative colitis model; and themodel is used for investigating the effectiveness of the strain of the invention for preventing the ulcerative colitis. The clostridiumbutyricum provided by the invention can be used for effectivelyrelieving the body weight loss, diarrhea and hematochezia of the mouse with the ulcerative colitis induced by the DSS and effectively improving the DAI (Disease Activity Index) grade; the mouse colontissue pathologic lesion of the mouse induced by DSS can be protected; the epithelial barrier completeness of the colon tissues can be enhanced; and non-toxicity and harmlessness are realized.

The invention provides a composition containing resveratrol and used for treating ulcerative colitis. The composition consists of the following components in parts by weight: 1-10 parts of resveratrol, 5-20 parts of a grape seed extract, 10-50 parts of prebiotics and an adhesive which is 2-5% of the total weight of other components, and the binder namely the adhesive is water or an alcohol solution of 80-95%. The components of the composition cooperate for common use, so that the in vivo cell factors can be regulated, and the inflammation can be restrained; and after experiment mice induced with dextran sulfate sodium are intervened with the composition, the symptom of acute colitis is relieved, the weight reduction is restrained, and the colon shrinking degree is obviously improved. The composition preparation is harmonious in color after being brewed and is moderate in mouth feel.

The invention discloses an establishment method of a mouse influence model on an ulcerative colitis by selenized oligomeric aminopolysaccharide. Influences on the ulcerative colitis, induced by the fact that DSS (Dextran Sulfate Sodium) is mediated by the selenized oligomeric aminopolysaccharide (LSA), are detected through a living mouse model. A research result shows that compared with a DSS model group, the content of mouse blood DAO (Diamine Oxidase), lysozyme and D-LAC of an LSA group is reduced, and the content of tight junction protein and mucoprotein is increased; HE dyeing and scanningelectron microscope display structures are obvious and are more complete and the permeability of a mouse intestinal mucosa is reduced; the LSA can be used for remarkably alleviating inflammatory factor abnormal expression caused by the DSS through inhibiting a phosphorylation level of an NF-kappaB p65 related signal pathway, and inhibiting the raising of a colitis related oxidization index MDA and oxidase iNOS concentration.

Experiments indicate that chlamydia muridarum (CM) can antagonize wild mice ulcerative colitis induced by dextran sulfate sodium (DSS), suggest that the CM has anti-ulcerative colitis effect, and theCM can be used for preparing anti-ulcerative colitis drugs.

The invention relates to the field of biomedicines, and in particular relates to an effect and a mechanism of extract of root of Hainan devilpepper on dextran sulfate sodium colitis in mice, and the extract can interfere with signaling pathways of NF-kB and MAPKs. The extract is obtained by drying the root of Hainan devilpepper at 40 DEG C, filtering with a 0.7% ammonium oxalate solution for extraction, centrifuging residue, adjusting pH to 4.40 with HCL, again centrifuging, precipitating the residue with ethanol, and drying after centrifugation.

The invention belongs to the technical field of medicines, and particularly relates to a salvianic acid A sodium oral self-assembled liposome for treating ulcerative colitis and a preparation method thereof. The salvianic acid A sodium oral self-assembled liposome for treating ulcerative colitis prepared by the method disclosed by the invention is prepared by taking salvianic acid A sodium, phospholipid, cholesterol, chitosan and sodium alginate as raw materials and adopting a reversed-phase evaporation method and an LbL self-assembly technology. A mouse experiment of the DSS (dextran sulfate sodium) induced ulcerative colitis proves that the oral salvianic acid A sodium self-assembled liposome prepared by the invention has the effects of improving clinical symptoms of mice with colitis, reducing the content of proinflammatory factors TNF-alpha, IF-6 and IF-1beta in serum of the mice with ulcerative colitis, increasing the content of anti-inflammatory factor IL-10 and alleviating intestinal flora imbalance of mice with ulcerative colitis, thereby having a relatively good medicine effect on treating ulcerative colitis.

The invention discloses a building method for a chicken enteritis model. The method comprises the following steps of (1) dissolving dextran sulfate sodium with a molecular weight of 36-50kDa in chicken drinking water to prepare 0.75-2.5% by weight of a dextran sulfate sodium solution, wherein the dextran sulfate sodium solution is used immediately after being prepared; (2) selecting a 14-18-day-age healthy quick-growth chicken as an object for building the chicken enteritis model; and (3) feeding the selected quick-growth chicken in a chicken house, and enabling the chicken to freely drink the dextran sulfate sodium solution prepared in the step (1) for more than 10 days. The building method for the chicken enteritis model is simple and convenient in operation; the effective dose range of the dextran sulfate sodium solution is wide, so that enteritis models of different pathological degrees can be built; and the method can be suitable for large-scale popularization and application in experiments.

The invention discloses a wheat germ oil bath salt comprises, based on the weight percentage, following compositions: 2 to 4 parts of wheat germ oil, 3 to 5 parts of dextran sulfate sodium, 0.2 to 0.4 part of sodium carboxymethyl inulin and 100 parts of sodium chloride. The wheat germ oil bath salt in the invention can remove dirt in human body's pores and can prevent color spots, shading and pigmentation.

The invention discloses an application of dehydrolovastatin to preparation of an anti-inflammatory bowel disease medicament. The prevention and control actions and the action mechanism of the dehydrolovastatin on a mouse inflammatory bowel disease induced by dextran sulfate sodium are disclosed for the first time through tests of building a mouse acute inflammatory bowel disease model, observing the treatment effect of the dehydrolovastatin on the inflammatory bowel disease, and the like. The dehydrolovastatin significantly inhibits the levels of proinflammatory factors TNF-alpha, IL-6 and IL-17 by inhibiting an NF-kappa B signal path, raises the level of an anti-inflammatory factor IL-10, and plays a role in preventing the mouse inflammatory bowel disease induced by 4-percent DSS (Dextran Sulfate Sodium Salt).

The invention discloses an application of total saponins of panax japonicus in preparation of ulcerative colitis resisting medicines. According to the application, the prevention and treatment action and action mechanism of the total saponins of panax japonicus to dextran sulfate sodium induced mouse ulcerative colitis are researched through a series of tests, i.e., extracting the total saponins of panax japonicus, carrying out an acute toxicity test on the total saponins of panax japonicus, modeling a mouse acute ulcerative colitis model and observing the therapeutic action of the total saponins of panax japonicus on ulcerative colitis, and the influence on NF-[kappa]B and PPAR-gamma signal channels caused by the total saponins of panax japonicus is disclosed for the first time. The total saponins of panax japonicus have the effects of treating both symptoms and root causes and being safe and effective during the treatment of the ulcerative colitis.

The invention researches the anti-inflammatory activity of DSS (Dextran Sulfate Sodium) inducted colitis model for paeoniflorin and paeoniflorin metabolism pigment I. An experiment result indicates that the paeoniflorin metabolism pigment I has a good treatment effect on ulcerative colitis. Compared with a control group and a paeoniflorin group, a C57BL / 6 mouse which orally takes the paeoniflorinmetabolism pigment I, the paeoniflorin metabolism pigment I is characterized in that a colon tissue damage degree is lightened, the mouse colon tissue damage degree of the low and high dosage medication administration team of the paeoniflorin metabolism pigment I is lightened, a tissue structure is clear in level, the infiltration of inherent layer inflammatory cells is reduced, the amount of cup-shaped cells is relatively increased, muscularis mucosa does not contain tissue edema and hyperaemia, and tissue forms are obviously recovered. The paeoniflorin metabolism pigment I is proved to havea good treatment effect on the ulcerative colitis.

The invention relates to application of Metrnl in preventing and treating ulcerative colitis. According to the application, a DSS (Dextran Sulfate Sodium) induced ulcerative colitis model is established by using Metrnl intestinal epithelium specific knock-out mice and corresponding reference wild mice, and results show that the Metrnl intestinal epithelium specific knock-out mice are suffered fromulcerative colitis which is conspicuously more serious than that of the reference wild mice, the intestinal mucosa erosion degrees of the Metrnl intestinal epithelium specific knock-out mice are conspicuously higher than those of the reference wild mice, and a Metrnl protein can be used as a novel effective medicine for preventing and treating ulcerative colitis. The invention provides a novel method for preventing and treating ulcerative colitis, and in addition, since the Metrnl protein self is an endogenous protein of human bodies, the Metrnl protein has very small possible side effects onhuman bodies and is very high in security as a potential medicine.

The invention belongs to the technical field of medicines, and discloses pomegranate rind tannin and application of punicalagin and granatin serving as effective components of the pomegranate rind tannin in preparation of medicines for treating ulcerative colitis. After the pomegranate rind tannin is used for treating mouse ulcerative colitis induced by dextran sulfate sodium salt, the body weight, the disease activity index, the colorectum length, the colorectum mucous membrane form and the goblet cell number are improved to a certain extent compared with a model group; therefore, the pomegranate rind tannin has a certain treatment effect on ulcerative colitis. The effective components punicalagin and granatin in the pomegranate rind tannin are independently or jointly administered, so that the pomegranate rind tannin has a very good effect on ulcerative colitis, and drug combination is optimal.

The invention provides application of an MG53 / MG53 mutant-containing composition in preparation of a drug for preventing and treating the inflammatory bowel disease. The mutant is non-polar amino acidalanine mutated from a serine site in the Coiled-coil structural domain of MG53. A mouse ulcerative colitis model is built through induction of dextran sulfate sodium (DSS); 5-aminosalicylic acid (5-ASA) is used as a positive drug for contrast; evaluation of a disease activity index (DAI), the length of a colon, a weight change and pathological changes of a colon tissue verifies that the composition has an obvious inhibition effect on the DSS-induced colitis.

The invention discloses a sample pretreatment solution for quantitative vitamin D detection. The solution comprises normal saline, dextran sulfate sodium salt and a beta-isotropism blocking agent. Thedextran sulfate sodium salt and the beta-isotropism blocking agent can be used to fully separate 25-hydroxyvitamin D to be analyzed from binding protein to a certain extent. Non-specific interferenceeffect in a serum matrix is reduced, the sample can be well separated in the further separation and purification process, a high-quality to-be-analyzed object can be obtained from the treated sample,and the quantitative detection accuracy of the vitamin D is improved.

The invention relates to application of Extzw in preparation of anti-ulcerative colitis drugs for a digestive tract. The extract is a supernatant and precipitate obtained by water extraction and alcohol precipitation of Balanophora involucrata. After the supernatant is decompressed to recovery ethanol, an extract of an ethyl acetate portion and an extract of an n-butanol portion are separately obtained by extracting ethyl acetate and n-butanol sequentially, and the precipitate is washed and dried by alcohol to obtain an extract of a water extraction and alcohol precipitation portion. The Extzwand the extracts of the ethyl acetate portion and the water extraction and alcohol precipitation portion prepared from the Extzw have obvious improvement on dextran sulfate sodium (DSS)-induced ulcerative colitis in mice, can be applied to the preparation of the anti-ulcerative colitis drugs for the digestive tract, and even to the preparation of other drugs for the treatment of intestinal inflammatory diseases.

The invention belongs to the technical field of biology, particularly relates to an insect cell maintenance liquid for increasing the expression amount of hog cholera virus E2 recombinant proteins and a preparation method thereof. To be specific, baculovirus is specifically added in an equilibrium liquid-phosphate buffer solution(1 * PBS) to synthesize the limiting amino acids of E2 proteins, dextran sulfate sodium and polyether F-68 which are used as the maintenance liquid to replace an insect cell cell culture medium used for inoculating recombinant baculovirus. With the same culture conditions, same cell quantity and same virus-inoculating quantity, compared with the insect cell culture medium, the insect cell maintenance liquid for increasing the expression amount of hog cholera virus E2 recombinant proteins increases the infection of cells within an unit quantity, the production quantity of the recombinant baculovirus and the secretion amount of the E2 recombinant proteins.

The invention researches the anti-inflammatory activity of DSS (Dextran Sulfate Sodium) inducted colitis model for paeoniflorin and paeoniflorin metabolism pigment I. An experiment result indicates that the paeoniflorin metabolism pigment I has a good treatment effect on ulcerative colitis. Compared with a control group and a paeoniflorin group, a C57BL / 6 mouse which orally takes the paeoniflorinmetabolism pigment I, the paeoniflorin metabolism pigment I is characterized in that a colon tissue damage degree is lightened, the mouse colon tissue damage degree of the low and high dosage medication administration team of the paeoniflorin metabolism pigment I is lightened, a tissue structure is clear in level, the infiltration of inherent layer inflammatory cells is reduced, the amount of cup-shaped cells is relatively increased, muscularis mucosa does not contain tissue edema and hyperaemia, and tissue forms are obviously recovered. The paeoniflorin metabolism pigment I is proved to havea good treatment effect on the ulcerative colitis.

The invention relates to application of Metrnl in preventing and treating ulcerative colitis. According to the application, a DSS (Dextran Sulfate Sodium) induced ulcerative colitis model is established by using Metrnl intestinal epithelium specific knock-out mice and corresponding reference wild mice, and results show that the Metrnl intestinal epithelium specific knock-out mice are suffered fromulcerative colitis which is conspicuously more serious than that of the reference wild mice, the intestinal mucosa erosion degrees of the Metrnl intestinal epithelium specific knock-out mice are conspicuously higher than those of the reference wild mice, and a Metrnl protein can be used as a novel effective medicine for preventing and treating ulcerative colitis. The invention provides a novel method for preventing and treating ulcerative colitis, and in addition, since the Metrnl protein self is an endogenous protein of human bodies, the Metrnl protein has very small possible side effects onhuman bodies and is very high in security as a potential medicine.

The present invention shows by experiments that mouse Chlamydia (Chlamydia muridarum, CM) can antagonize the wild-type mouse ulcerative colitis induced by dextran sulfate sodium (Dextran Sulfate Sodium, DSS), suggesting that CM has anti-ulcerative colitis It can be used to prepare anti-ulcerative colitis drugs.

The invention discloses a wheat germ oil bath salt comprises, based on the weight percentage, following compositions: 2 to 4 parts of wheat germ oil, 3 to 5 parts of dextran sulfate sodium, 0.2 to 0.4 part of sodium carboxymethyl inulin and 100 parts of sodium chloride. The wheat germ oil bath salt in the invention can remove dirt in human body's pores and can prevent color spots, shading and pigmentation.

The invention discloses a brand new application of a compound shown in a formula 1, namely the compound is used for preparing a medicine for treating an inflammatory bowel disease (IBD) by inhibiting activation of NLRP3 inflammasome and maturation and release of IL-1beta. According to the present invention, the research results show that the compound represented by the formula 1 can inhibit the mouse colitis induced by dextran sulfate sodium salt (DSS), and the application mechanism of the compound represented by the formula 1 mainly comprises that the activation of the NLRP3 inflammasome is inhibited so as to reduce the release of IL-1beta so as to inhibit inflammation; by recording and analyzing the weight loss, the disease activity index (DAI) score and the colon shortening condition of a DSS-induced colitis model mouse and the expression condition of IL-1beta and the like in the mouse colon tissue, the inhibition effect of the compound in the formula 1 on the colitis disease of the DSS-induced mouse colitis model is evaluated.

The invention provides a composition with skin whitening and moisturizing effects. The composition is composed of a rhizoma smilacis scobinicaulis extract, flos rosae rugosae hydrolat, flos natricariae chamomillae hydrolat, sodium hyaluronate, butanediol, propylene glycol, sodium chloride, EDTA, dextran sulfate sodium and water. A formula of the composition is free of a toxic ingredient, free of askin irritation ingredient, safe and effective. The composition is convenient to use and short in onset time, and can effectively improve the skin brightness and improve the moisture content of the skin.

The invention discloses an application of a turmeric and rhzoma zingiberis purrurei stomach pain recipe to preparation of medicines for treating inflammatory bowel diseases. The turmeric and rhzoma zingiberis purrurei stomach pain recipe is a mixture which is obtained by performing mixing and extracting on turmeric, rhzoma zingiberis purrurei, delavay stephania roots, grassleaf sweetflag rhizomesand semen integrifoliae through the weight ratio relationship of 1:1:1:1:1. Tests prove that the turmeric and rhzoma zingiberis purrurei stomach pain recipe can notably improve mouse colitis diseasesinduced by dextran sulfate sodium, the activity indexes of mouse diseases can be notably reduced, and the mouse colon contraction in length caused by modeling can be obviously improved. The vitality of MPO in serum can be notably reduced, the content of proinflammatory factors IL-1 beta, IL-6 and IL-1 beta in colon tissues can be notably reduced, and the application has notable activity for resisting ulcerative colitis, and has favorable application prospects in preparation of medicines for treating inflammatory bowel diseases.

The invention discloses an establishment method of a mouse influence model on an ulcerative colitis by selenized oligomeric aminopolysaccharide. Influences on the ulcerative colitis, induced by the fact that DSS (Dextran Sulfate Sodium) is mediated by the selenized oligomeric aminopolysaccharide (LSA), are detected through a living mouse model. A research result shows that compared with a DSS model group, the content of mouse blood DAO (Diamine Oxidase), lysozyme and D-LAC of an LSA group is reduced, and the content of tight junction protein and mucoprotein is increased; HE dyeing and scanningelectron microscope display structures are obvious and are more complete and the permeability of a mouse intestinal mucosa is reduced; the LSA can be used for remarkably alleviating inflammatory factor abnormal expression caused by the DSS through inhibiting a phosphorylation level of an NF-kappaB p65 related signal pathway, and inhibiting the raising of a colitis related oxidization index MDA and oxidase iNOS concentration.